US 11,701,331 B2
Toxic aldehyde related diseases and treatment
Todd Brady, Carlisle, MA (US); Scott Young, E. Falmouth, MA (US); William A. Kinney, Newtown, PA (US); and Kenneth J. Mandell, Arlington, MA (US)
Assigned to Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed by Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed on Apr. 12, 2021, as Appl. No. 17/227,568.
Application 17/227,568 is a continuation of application No. 16/773,654, filed on Jan. 27, 2020, granted, now 11,007,157.
Application 16/773,654 is a continuation of application No. 16/277,865, filed on Feb. 15, 2019, granted, now 10,588,874, issued on Mar. 17, 2020.
Application 16/277,865 is a continuation of application No. 16/262,364, filed on Jan. 30, 2019, granted, now 10,543,181, issued on Jan. 28, 2020.
Application 16/262,364 is a continuation of application No. 15/590,708, filed on May 9, 2017, granted, now 10,213,395, issued on Feb. 26, 2019.
Application 16/277,865 is a continuation of application No. 15/590,708, filed on May 9, 2017, granted, now 10,213,395, issued on Feb. 26, 2019.
Application 15/590,708 is a continuation of application No. 14/760,039, granted, now 9,687,481, issued on Jun. 27, 2017, previously published as PCT/US2014/012762, filed on Jan. 23, 2014.
Claims priority of provisional application 61/901,796, filed on Nov. 8, 2013.
Claims priority of provisional application 61/755,613, filed on Jan. 23, 2013.
Prior Publication US 2021/0275469 A1, Sep. 9, 2021
Int. Cl. A61K 31/137 (2006.01); A61K 31/47 (2006.01); A61K 31/197 (2006.01); A61K 8/44 (2006.01); A61K 8/41 (2006.01); A61Q 19/00 (2006.01); A61K 8/49 (2006.01); A61Q 19/08 (2006.01); A61K 31/13 (2006.01); A61K 31/423 (2006.01); A61K 31/438 (2006.01); A61K 31/435 (2006.01); C08K 5/04 (2006.01); C08K 5/08 (2006.01); C08K 5/18 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 8/41 (2013.01); A61K 8/44 (2013.01); A61K 8/49 (2013.01); A61K 8/4926 (2013.01); A61K 31/13 (2013.01); A61K 31/197 (2013.01); A61K 31/423 (2013.01); A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/47 (2013.01); A61Q 19/00 (2013.01); A61Q 19/08 (2013.01); C08K 5/04 (2013.01); C08K 5/08 (2013.01); C08K 5/18 (2013.01)] 41 Claims
OG exemplary drawing
 
1. A method of treating scleritis, comprising:
administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein,
X is CH; Z is N; and Y is C with the —NH2 attached;
p is 0, 1, 2, or 3;
each RB is independently a halogen, hydroxyl, carbamoyl, amino, or aryl;
RA is

OG Complex Work Unit Chemistry
 and
each Qa is independently a C1-C6 straight chain alkyl.